Bank of America Corp DE lowered its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 64.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 149,697 shares of the company's stock after selling 269,320 shares during the period. Bank of America Corp DE's holdings in GoodRx were worth $696,000 as of its most recent filing with the SEC.
Other large investors also recently added to or reduced their stakes in the company. IMC Chicago LLC bought a new position in GoodRx during the 4th quarter worth approximately $304,000. Geode Capital Management LLC increased its stake in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after buying an additional 89,032 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in GoodRx during the 4th quarter valued at $358,000. Barclays PLC increased its position in shares of GoodRx by 18.4% in the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after acquiring an additional 25,815 shares during the period. Finally, Northern Trust Corp increased its position in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after acquiring an additional 50,256 shares during the period. Hedge funds and other institutional investors own 63.77% of the company's stock.
GoodRx Stock Down 2.5%
Shares of GoodRx stock traded down $0.11 on Friday, reaching $4.37. The company's stock had a trading volume of 1,039,504 shares, compared to its average volume of 1,386,928. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -145.67, a P/E/G ratio of 2.46 and a beta of 1.16. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. GoodRx Holdings, Inc. has a 52 week low of $3.68 and a 52 week high of $9.26. The firm's fifty day simple moving average is $4.26 and its two-hundred day simple moving average is $4.53.
GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The business's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.08 earnings per share. Equities analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.
Insider Buying and Selling at GoodRx
In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $4.09, for a total value of $43,668.93. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 4.53% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on the company. Wells Fargo & Company cut their target price on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. UBS Group dropped their price target on GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. The Goldman Sachs Group reduced their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Finally, Truist Financial decreased their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a report on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, GoodRx currently has an average rating of "Moderate Buy" and an average target price of $6.55.
Read Our Latest Report on GDRX
About GoodRx
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Stories
Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
